Test Price
550 AED✅ Home Collection Available
Immunophenotyping by Flow Cytometry (CD13) Test in UAE – 550 AED
Executive Summary & Core Metrics
Clinical Excellence Delivered with Hospital-Grade Precision
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Complimentary Telephonic Post‑Test Result Interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Immunophenotyping by Flow Cytometry (CD13) Test is a definitive laboratory assay that quantifies the CD13 surface antigen on peripheral blood or bone marrow cells, enabling precise subtyping of myeloid neoplasms such as acute myeloid leukemia. This multiparameter flow‑cytometric test delivers same‑day results, supporting urgent oncology decision‑making in line with UAE clinical standards.
| Specification | Our CD13 Test | Closest Alternative (IHC on Biopsy) |
|---|---|---|
| Precision | Quantitative, multiparametric | Semi‑quantitative, subjective scoring |
| Methodology | Fluorescence‑based flow cytometry | Immunohistochemical staining |
| Turnaround | Same day (report by 9 am if sample drawn daily by 9 am) | 24–48 hours |
| Sample Integrity | Immediate cold‑chain processing | Fixed tissue, less cellular detail |
Physician Insight & Safety Protocols
“Flow cytometry provides quantitative, multi‐parametric data that is indispensable for the diagnosis and subclassification of myeloid malignancies. However, CD13 expression alone must be interpreted alongside morphological, cytogenetic, and clinical findings. Patients should never alter or discontinue prescribed therapies without direct consultation with their treating physician.”
— Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011
Advisory: Medication Continuation
⚠️ Do Not Discontinue Prescribed Medication
The CD13 test is a diagnostic aid only. It does not replace ongoing therapy. Patients must continue all prescribed treatments unless explicitly instructed otherwise by their doctor. Abrupt discontinuation may lead to disease progression or adverse outcomes.
Exclusion Criteria & Emergency Red Flags
Patient Safety & Exclusion Criteria
- Exclusion: Known allergy to heparin (if green‑top tube is used); active severe infection requiring urgent intervention; inability to provide the minimum sample volume.
- ER Red Flags: If you experience sudden high fever, uncontrolled bleeding, severe bone pain, or neurological changes before your appointment, seek emergency medical care immediately.
Patient FAQ & Clinical Guidance
1. What is immunophenotyping by flow cytometry for CD13?
Immunophenotyping by flow cytometry for CD13 is a laboratory test that measures the CD13 protein on blood or marrow cells, helping hematologists diagnose and monitor acute myeloid leukemia and other myeloid malignancies. The assay uses fluorescent antibodies to identify CD13‑positive cell populations with high sensitivity and speed.
2. How should I prepare for the CD13 test?
No fasting is required; however, you must provide a brief clinical history and avoid discontinuing any medication without medical advice. Our phlebotomist will collect the samples in specific tubes (lavender EDTA and green sodium heparin) and transport them at controlled room temperature immediately. Collection occurs exclusively within a hospital setting for safety reasons.
3. What do the results of the CD13 test mean?
A positive CD13 result indicates the presence of myeloid lineage cells, but interpretation requires correlation with a full panel of markers; it is not a standalone cancer diagnosis. Your hematologist will combine this data with morphology and genetics to determine the exact leukemia subtype.
4. How long does it take to get the results?
Results are typically available the same day. If the sample is collected by 9:00 AM, the report is issued by 9:00 PM on the same business day. For samples collected later, results are delivered by the end of the next working day.
UAE Regulatory & Data Privacy Adherence
This service operates in full compliance with UAE Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All clinical data are processed under ISO 9001:2015 validated protocols (Cert. INT/EGQ/2509DA/3139). Patient consent adheres to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | Immunophenotyping by Flow Cytometry (CD13) |
| Price (AED) | 550 AED |
| Turnaround Time | Same day (if sample received by 9:00 AM) Otherwise, next business day |
| Sample Type / Matrix | Whole Blood or Bone Marrow Aspirate (hospital collection only) |
| Methodology Used | Fluorescence‑based Flow Cytometry (Multiparameter) |
| ICD-10-CM Code | C92.0 (Acute myeloblastic leukemia, minimal differentiation) |
| LOINC Code | 11066-5 (Cells.CD13 flow cytometry in Blood) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians